|
Dr. Marco Attilio Eugenio Zarbin, M.D., Ph.D., F.A.C.S. was born in Milano, Italy on 11/20/56, received a baccalaureate from the Gilman School (cum laude) in 1974, and received a B.A. (biochemistry) from Dartmouth College (Phi Beta Kappa, summa cum laude, with highest distinction) in 1978. He matriculated to the Johns Hopkins University School of Medicine in 1978 and entered their Medical Scientist Training Program in 1980. Dr. Zarbin was awarded degrees in medicine (M.D.) and pharmacology (Ph.D.) in 1984 and graduated from the Hopkins Medical School as a member of the Alpha Omega Alpha honor society. Dr. Zarbin was a medical intern at the Dartmouth-Hitchcock Medical Center in Hanover, N.H. He completed an ophthalmology residency at the Wilmer Ophthalmological Institute, the Johns Hopkins Hospital from 1985-1988. As a resident, Dr. Zarbin was the co-recipient of the Francis S. Schwentker Award for resident research. Dr. Zarbin completed fellowships in vitreoretinal surgery and in medical retinal disease at the Wilmer Ophthalmological Institute as a Heed Ophthalmic Foundation Fellow and was an Assistant Chief of Service at Wilmer in 1989. He received certification from the American Board of Ophthalmology in November 1989. From 1990-1993, Dr. Zarbin served as an Assistant Professor of Ophthalmology at the University of California, San Francisco and as Chief of the division of Ophthalmology at the Department of Veterans Affairs Medical Center, San Francisco. Dr. Zarbin was appointed Chair of the Institute of Ophthalmology and Visual Science, New Jersey Medical School and Chief of Ophthalmology at University Hospital in Newark, N.J. in January 1994. He is a Professor of Ophthalmology and Neuroscience at the New Jersey Medical School. Dr. Zarbin is co-Director of the Ocular Cell Transplantation Laboratory and the co-Director of the Center for Macular Degeneration Research at UMDNJ. His research is focused on developing new surgical treatments for age-related macular degeneration, the leading cause of blindness in persons over age 55 in the United States and Western Europe. This research, which involves the transplantation of specialized cells, is supported by grants from the National Eye Institute, the Department of Veterans Affairs, the Lincy Foundation, and the Foundation Fighting Blindness. Dr. Zarbin has co-authored 112 peer-reviewed scientific publications, 33 book chapters, and has co-edited one book on age-related macular degeneration. Dr. Zarbin currently serves as Past President of the Board of Trustees of the Association of University Professors of Ophthalmology (AUPO). (The AUPO comprises all ophthalmology departments with resident training programs in the United States and Canada.) Dr. Zarbin is an Associate Editor of Investigative Ophthalmology and Visual Science, the most widely cited eye research journal in the world, and is a member of the Editorial Board of Survey of Ophthalmology. Dr. Zarbin is a Vice Chair of the Scientific Advisory Board of the Foundation Fighting Blindness. Dr. Zarbin is a member of the board of Governors (ex officio) of the New Jersey Academy of Ophthalmology and the National Advisory Council of the National Institutes of Health. In addition, he is a member of the American Ophthalmological Society, the Retina Society, the Macula Society, and the Vitreous Society. In the past Dr. Zarbin served as a member of the Preferred Practice Pattern Committee (Retina Panel) of the American Academy of Ophthalmology, Chair of the Retinal Cell Biology Program Planning Committee of the Association of Research in Vision and Ophthalmology (ARVO), and Chair of the Professional Development and Education Committee of ARVO. (ARVO is the largest eye research organization in the world.) Dr. Zarbin's clinical interests are limited to medical and surgical diseases of the retina and vitreous with special expertise in age-related macular degeneration, trauma management, complex retinal detachment (including retinopathy of prematurity), and surgery of the macula (including macular holes, subretinal hemorrhage, and subretinal neovascularization). He has been listed among the “Best Doctors in America”. |
